加载中
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
前收盘价
US$3.645
+US$0.115 · +3.26%
盘前
US$3.5741
−US$0.0709 · -1.95%
10月12日 8:41 ET
盘中时间采用ET。市场数据可能有所延迟。
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
日内区间
当前US$3.645
52周区间
当前US$3.645
盘中时间采用ET。市场数据可能有所延迟。
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States. The company's portfolio features two investigational products, LNZ100 and LNZ101, both of which are currently undergoing late-stage Phase III clinical trials as potential solutions for presbyopia. Corporate operations for LENZ Therapeutics are situated in Del Mar, California.
日内区间
当前US$3.645
52周区间
当前US$3.645
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1908.8万 USD | — | — | 1500万 USD | — |
| 销货成本 | 70.5万 USD | 5.8万 USD | — | — | 73.4万 USD |
| 毛利 | 1838.3万 USD | −5.8万 USD | — | 1500万 USD | −73.4万 USD |
| 研究与开发 | 1867万 USD | 2980.1万 USD | 5950.4万 USD | 2112.5万 USD | 3793.2万 USD |
| 销售、一般及管理费用 | 9085.1万 USD | 2875.1万 USD | 1292.5万 USD | 435.8万 USD | 2177.7万 USD |
| 营业费用 | 1.1亿 USD | 5855.2万 USD | 7242.9万 USD | 2548.3万 USD | 5970.9万 USD |
| 利息收入 | 975.6万 USD | 855.3万 USD | 218.9万 USD | — | — |
| 折旧和摊销 | 28.7万 USD | 5.8万 USD | 1.5万 USD | 8000 USD | 73.4万 USD |
| 营业利润 | −9113.8万 USD | −5861万 USD | −7242.9万 USD | −1048.3万 USD | −6044.3万 USD |
| 净利润 | −8212.7万 USD | −4976.9万 USD | −6996.8万 USD | −1081.1万 USD | −7076万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$7.00
上涨空间 92.04%| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2024年3月22日 | US$1.03Weekly | 2024年3月18日 | — |
股息 | 2024年3月15日 | US$1.03Weekly | — | — |
除息 2024年3月22日
US$1.03
Weekly
2024年3月18日登记
除息 2024年3月15日
US$1.03
Weekly
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI427.01万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM194.25万0.00%787.4亿 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF131.87万0.00%954亿 USD0.05%US$235+0.80%
Fidelity Enhanced Small Cap ETFFESM87.27万0.01%64.1亿 USD0.28%US$45.46+0.46%
iShares Biotechnology ETFIBB74.77万0.01%108.2亿 USD0.44%US$206.49+3.00%
Vanguard Russell 2000 ETFVTWO61.52万0.00%180亿 USD0.06%US$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA41.57万0.00%218.24亿 USD0.03%US$32.79+0.40%
Vanguard Health Care ETFVHT29.95万0.00%220亿 USD0.09%US$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFFidelity Enhanced Small Cap ETFFESMiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
